Innealta Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Innealta Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-175	Closed	-$294	–	1028
2024 Q2	$294	Buy	+175	New	+$314	﹤0.01%	1553

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Innealta Capital's LXRX Position: Q3 2024 in Review

Innealta Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2024, closing a stake of 175 shares — an estimated $294 sold.

Innealta Capital first reported a position in LXRX in Q2 2024 and held it in 1 quarter. The position peaked at $294 in Q2 2024. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2024.

Innealta Capital reported no remaining Lexicon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 175 Lexicon Pharmaceuticals shares in Q3 2024, an estimated $294.
Innealta Capital first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Innealta Capital's Lexicon Pharmaceuticals position peaked at $294 in Q2 2024.
137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.